Paul Latkany, MD

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Article:29

Review Article:5

Letter:3

Chapter:2

Recent Artifacts

• Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview
• Building Programs to Eradicate Toxoplasmosis Part II: Education
• Building Programs to Eradicate Toxoplasmosis Part III: Epidemiology and Risk Factors
• Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances “Take a Village”
• A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab
• The joint pathology center/vision center of excellence approach to analyzing intra-ocular "foreign bodies"
• Interobserver Agreement Among Uveitis Experts on Uveitic Diagnoses: The Standardization of Uveitis Nomenclature Experience
• Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study
• Outcome of Treatment of Uveitic Macular Edema: the Multicenter Uveitis Steroid Treatment Trial 2-Year Results
• Lack of consensus in the diagnosis and treatment for ocular tuberculosis among uveitis specialists

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Latkany has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.